newsfilter
← Earnings
Earnings Releases·

Obsidian Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss for Q3 2026 widened to $50.7 million ($1.23/share) from $28.5 million in the prior year period, driven by a $15.1 million in-process R&D charge from the Galera transaction and increased G&A expenses; however, cash, cash equivalents, and marketable securities surged to $324.4 million from $80.5 million at year-end 2025.
  • The company completed a $350 million oversubscribed private placement and transitioned to positive stockholders' equity of $320.6 million, up from a $266.0 million deficit, while listing on Nasdaq under the ticker "OBX" in August 2026.
  • Clinical updates for amsoki-cel in ICI-resistant advanced melanoma showed a 67% objective response rate and a median progression-free survival of 8.3 months with a favorable safety profile; enrollment for the registration-enabling Agni-01 cohort is on track to complete by Q1 2027, with topline data expected by year-end 2027.
  • Management projects current cash resources will support operations through the second half of 2028, with Phase 1 data for the NSCLC program anticipated in the first half of 2027.
Company
OBSIDIAN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology